Compare Regeneron Pharmaceuticals Inc (REGN) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Global X Uranium ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Global X Uranium ETF trades at $40.9. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Global X Uranium ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| REGN | URA | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $812.27 | $61.81 |
52-Week Low | $545.46 | $36.45 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
URA trades at $38.64, down 0.28% on the day, with technical indicators showing a bearish trend from moving averages but oversold RSI signals. The ETF holds $6.29 billion in assets and benefits from strong narratives around AI-driven power demand and nuclear energy expansion, though key financial ratios are not publicly detailed for the fund itself. Recent news highlights uranium's role in meeting data center electricity needs.
Outlook is supported by structural demand trends, but high expense ratios and competition from pure-play uranium funds pose risks. The fund's performance hinges on uranium price movements and policy developments, with current technical weakness suggesting caution in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
